The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis which typically begins in early adulthood and impacts on healthcare resource utilisation and the ability to work. Previous studies examining the cost of AS have relied on patient-reported questionnaires based on recall. This study uses a combination of patient-reported and linked-routine data to examine the cost of AS in Wales, UK. METHODS: Participants in an existing AS cohort study (n = 570) completed questionnaires regarding work status, out-of-pocket expenses, visits to health professionals and disease severity. Participants gave consent for their data to be linked to routine primary and secondary care clinical datasets. Health resource costs were calculated using a bottom-up micro-costing approach. Human capital costs methods were used to estimate work productivity loss costs, particularly relating to work and early retirement. Regression analyses were used to account for age, gender, disease activity. RESULTS: The total cost of AS in the UK is estimated at £19016 per patient per year, calculated to include GP attendance, administration costs and hospital costs derived from routine data records, plus patient-reported non-NHS costs, out-of-pocket AS-related expenses, early retirement, absenteeism, presenteeism and unpaid assistance costs. The majority of the cost (>80%) was as a result of work-related costs. CONCLUSION: The major cost of AS is as a result of loss of working hours, early retirement and unpaid carer's time. Therefore, much of AS costs are hidden and not easy to quantify. Functional impairment is the main factor associated with increased cost of AS. Interventions which keep people in work to retirement age and reduce functional impairment would have the greatest impact on reducing costs of AS. The combination of patient-reported and linked routine data significantly enhanced the health economic analysis and this methodology that can be applied to other chronic conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been shown that using linked health data is an economic and effective alternative to performing de novo longitudinal studies, including rare conditions.24 25”
From Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case–control comparison (2019) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Călin, A. (1994) · PubMed · Cited by 3,241
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304050-00006 · Cited by 3,071
Călin, A., Garrett, S., Whitelock, H., Kennedy, L. G., O'Hea, J., MALLORIE, P. A., & Jenkinson, T. (1994) · PubMed · Cited by 2,329
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-70 · Cited by 1,833
The Work Limitations Questionnaire
Lerner, D., Amick, B. C., Rogers, W. H., Malspeis, S., Bungay, K., & Cynn, D. (2001) · Medical Care · doi:10.1097/00005650-200101000-00009 · Cited by 971
Cost-of-Illness Methodology: A Guide to Current Practices and Procedures
Hodgson, T. A., & Meiners, M. R. (1982) · The Milbank Memorial Fund Quarterly. Health and Society · doi:10.2307/3349801 · Cited by 668
The SAIL databank: linking multiple health and social care datasets
Lyons, R. A., Jones, K. H., John, G., Brooks, C. J., Verplancke, J.-P., Ford, D. V., Brown, G., & Leake, K. (2009) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-9-3 · Cited by 638
Estimating the cost of illness.
Rice, D. P. (1967) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.57.3.424 · Cited by 629
The SAIL Databank: building a national architecture for e-health research and evaluation
Ford, D. V., Jones, K. H., Verplancke, J.-P., Lyons, R. A., John, G., Brown, G., Brooks, C. J., Thompson, S., Bodger, O., Couch, T., et al. (2009) · BMC Health Services Research · doi:10.1186/1472-6963-9-157 · Cited by 559
Cited by
Demmler, J. C., Atkinson, M. D., Reinhold, E. J., Choy, E., Lyons, R. A., & Brophy, S. T. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031365 · Cited by 271
“26”
Self-citationKigozi, J., Jowett, S., Lewis, M., Barton, P., & Coast, J. (2017) · Value in Health · doi:10.1016/j.jval.2016.12.006 · Cited by 162
A Profile of the SAIL Databank on the UK Secure Research Platform
Jones, K. H., Ford, D. V., Thompson, S., & Lyons, R. A. (2019) · International Journal for Population Data Science · doi:10.23889/ijpds.v4i2.1134 · Cited by 170
Carlo, M. D., Lato, V., Carotti, M., & Salaffi, F. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0463-1 · Cited by 33
Franco, L., Sengupta, R., Wade, L., & Cazzola, D. (2021) · PeerJ · doi:10.7717/peerj.10623 · Cited by 33
Kanters, T. A., Stevanović, J., Huys, I., Vulto, A. G., & Simoens, S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00322 · Cited by 30
Lee, J. S., Oh, B., Lee, H., Song, Y. W., & Lee, E. Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192524 · Cited by 24
Song, Y., Wang, C., & Chen, H. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3563-3 · Cited by 18
Deodhar, A. A., Machado, P., Mørup, M. F., Taieb, V., Willems, D., Orme, M. E., Pritchett, D., & Gensler, L. S. (2023) · Rheumatology · doi:10.1093/rheumatology/kead598 · Cited by 18
Patients with rheumatic diseases share similar patterns of healthcare resource utilization
Mars, N., Kerola, A. M., Kauppi, M. J., Pirinen, M., Elonheimo, O., & Sokka‐Isler, T. (2019) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2018.1559878 · Cited by 16
Claudepierre, P., Fagnani, F., Cukierman, G., de Chalus, T., Joubert, J.-M., Laurendeau, C., Gourmelen, J., & Bréban, M. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.04.003 · Cited by 16
Claudepierre, P., den Bosch, F. E. V., Sarzi‐Puttini, P., Vastesaeger, N., Govoni, M., & Kachroo, S. (2019) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13526 · Cited by 14
Reveille, J. D., Hwang, M. C., Danve, A. S., Kafka, S. P., Peterson, S. L., Lo, K. H., Kim, L., Hsia, E. C., Chan, E. K. H., & Deodhar, A. A. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05342-7 · Cited by 13
Tu, L., Xie, Y., Liao, Z., Jiang, Y., Lv, Q., Cao, S., Wei, Q., & Gu, J. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.602334 · Cited by 11
Ogdie, A., Hwang, M. C., Veeranki, S. P., Portelli, A., Sison, S., Shafrin, J. T., Pedro, S., Kim, N., Yi, E., & Michaud, K. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.9.1008 · Cited by 11
Bernfort, L., Persson, J., Linderoth, C., & Ekberg, K. (2021) · Work · doi:10.3233/wor-213439 · Cited by 11
Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis
Purmonen, T. T., Törmälehto, S., Wahlman, H., & Puolakka, K. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1551227 · Cited by 9
Redeker, I., Callhoff, J., Hoffmann, F., Saam, J., Haibel, H., Sieper, J., Zink, A., & Poddubnyy, D. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-019-0678-8 · Cited by 9
Tužil, J., Mlcoch, T., Jirčíková, J., Závada, J., Nekvindová, L., Svoboda, M., Uher, M., Křístková, Z., Vencovský, J., Pavelká, K., et al. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1694900 · Cited by 8
An Overview of Adalimumab Therapy for Ankylosing Spondylitis
Михайловна, С. А., Gilavian, M. A., Melnik, E. V., Ших, Е. В., Петухов, А. Е., Gegechkori, V., Dementyev, S. P., Vlasov, A. M., & Ramenskaya, G. V. (2024) · Current Rheumatology Reviews · doi:10.2174/0115733971289295240223095751 · Cited by 8
Magrey, M., Wei, J. C., Yndestad, A., Bushmakin, A. G., Cappelleri, J. C., Dina, O., & Deodhar, A. A. (2023) · Arthritis Care & Research · doi:10.1002/acr.25267 · Cited by 7
Axial spondyloarthritis: emerging drug targets
Cherqaoui, B., Araujo, L. M. M., Glatigny, S., & Bréban, M. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1973429 · Cited by 9
Kiltz, U., van der Heijde, D. M. F. M., Boonen, A. E. R. C. H., Gensler, L. S., Hunter, T. M., Guo, J., Carlier, H., & Braun, J. (2023) · The Journal of Rheumatology · doi:10.3899/jrheum.220244 · Cited by 7
Neilson, A. R., Jones, G. T., Macfarlane, G. J., Pathan, E., & McNamee, P. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01429-x · Cited by 6
What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?
Zanghelini, F., Xydopoulos, G., Wilsher, S. H., Afolabi, O., Webb, D., Eddison, J., Ingram, T. A., Clark, C., Hamilton, J., Sengupta, R., et al. (2025) · Lara D. Veeken · doi:10.1093/rheumatology/keaf226 · Cited by 5
The direct and indirect costs of axial spondyloarthritis (axSpA) in Singapore
Kwan, Y. H., Kwoh, S., Phang, J. K., Cheen, M., Lim, K., Wang, C., Leung, Y.-Y., Koh, H., Østbye, T., Thumboo, J., et al. (2020) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13777 · Cited by 6
Himmler, S., Branner, J. C., & Ostwald, D. A. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0077 · Cited by 5
Masterclass: Axial spondyloarthritis for osteopaths and manual therapists
MacMillan, A., Corser, A., Clark, Z., McCrum, C., & Gaffney, K. (2021) · International journal of osteopathic medicine · doi:10.1016/j.ijosm.2021.03.005 · Cited by 5
Svedbom, A., Dalén, J., Ivergård, M., Borse, R. H., Black, C. M., Luttropp, K., & Kachroo, S. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01110-w · Cited by 4
Craemer, A. D., Deroo, L., Renson, T., Desimpele, I., Delmez, L., Decuman, S., Janssens, X., Boonen, A. E. R. C. H., Elewaut, D. S., Carron, P., et al. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac529 · Cited by 4
Rouse, P. C., Ingram, T. A., Standage, M., & Sengupta, R. (2024) · Rheumatology International · doi:10.1007/s00296-024-05557-w · Cited by 6
Cooksey, R., Rahman, M. A., Kennedy, J. I., Brophy, S. T., & Choy, E. (2021) · Rheumatology Advances in Practice · doi:10.1093/rap/rkab042 · Cited by 5
Self-citationJones, C., Payne, K., & Verstappen, S. M. M. (2020) · Quality of Life Research · doi:10.1007/s11136-020-02570-x · Cited by 4
Rudwaleit, M., Machado, P., Taieb, V., de Peyrecave, N., Hoepken, B., & Gensler, L. S. (2023) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x231189079 · Cited by 3
Bali, O., & Singla, S. K. (2024) · Indian Journal of Rheumatology · doi:10.1177/09733698241239709 · Cited by 6
Yazdany, J., Myslinski, R., Johansson, T., & Kazi, S. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.5640 · Cited by 3
Deodhar, A. A., Chakravarty, S. D., Shiff, N. J., Lo, K. H., Xu, S., Hsia, E. C., Danve, A. S., & Reveille, J. D. (2022) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001857 · Cited by 2
Axial Spondyloarthritis: Patient-Reported Impact in Europe
Garrido‐Cumbrera, M., Navarro‐Compán, V., Bundy, C., Mahapatra, R., Makri, S., Delgado-Domínguez, C. J., Plazuelo-Ramos, P., & Poddubnyy, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-97606-4 · Cited by 7
OP0069 The burden of ankylosing spondylitis: a population based study
Js, L., Lee, H. Y., Lee, E., Song, Y., & Ey, L. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.4020 · Cited by 2
Cortesi, P. A., Fornari, C., Gisondi, P., Iannone, F., Antonazzo, I. C., Aloisi, E., Fiocchi, M., Ritrovato, D., & Mantovani, L. G. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00404-3 · Cited by 1
Huang, L., Pan, Y., Tang, X., Ding, H., Wang, Q., Ma, Q., Liu, H., & Fang, H. (2025) · Trials · doi:10.1186/s13063-025-09096-y · Cited by 2
Claudepierre, P., Fagnani, F., Cukierman, G., de Chalus, T., Joubert, J.-M., Laurendeau, C., Gourmelen, J., & Bréban, M. (2019) · Revue du Rhumatisme · doi:10.1016/j.rhum.2019.07.007
Employment Status and Productivity
Garrido‐Cumbrera, M., Navarro‐Compán, V., Bundy, C., Mahapatra, R., Makri, S., de Sevilla, U., Plazuelo-Ramos, P., & Poddubnyy, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-97606-4_11
Almowil, Z. (2023) · Cronfa (Swansea University) · doi:10.23889/suthesis.62363
Fang, H., Pan, Y., Zhang, Y., Deng, Y., Li, X., Huang, L., Gu, H., Ding, Y., Hu, X., Liu, M., et al. (2025) · Musculoskeletal Care · doi:10.1002/msc.70131 · Cited by 1
Metadata
- Authors
- Cooksey, R., Husain, M. J., Brophy, S., Davies, H., Rahman, M. A., Atkinson, M. D., Phillips, C. J., & Siebert, S.
- Affiliations
- Swansea University (GB)
- Keele University (GB)
- University of Glasgow (GB)
- Corresponding author
- Cooksey, Roxanne
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-07-17
- Volume
- 10
- Issue
- 7
- Pages
- e0126105
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4506082
- OpenAlex
- W1908131837
- Cited by
- 53
- References
- 37
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 13 · 2020: 5 · 2019: 8 · 2018: 3 · 2017: 5 · 2016: 1
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Pfizer
- National Institute for Social Care and Health Research
- Medical Research Council (MR/K006525/1)
- Topics
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- ankylosing spondylitis, economic burden, work productivity loss, early retirement, absenteeism, presenteeism, out-of-pocket costs, health resource utilisation, functional disability, micro-costing, patient-reported outcomes, Wales
- MeSH terms
- Absenteeism, Adult, Aged, Chronic Disease, Cost-Benefit Analysis, Health Expenditures, Female, Humans, Male, Middle Aged, Surveys and Questionnaires, Retirement, Severity of Illness Index, Spondylitis, Ankylosing, Wales, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.